Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0278883 (
metastatic melanoma
)
6,224
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Melanoma is a malignant tumor and one of the most frequent metastatic cancers. This study was conducted to identify differential expression genes (DEGs) and single nucleotide variations (SNVs) in
metastatic melanoma
. We analyzed microarray data of GSE23056 downloaded from the Gene Expression Omnibus, including two normal samples (skinN1 and skinN2) and 2
metastatic melanoma
samples (skinT and lymphT). We not only compared DEGs in
metastatic melanoma
samples with normal samples (lymphT_skinN and skinT_skinN), but also compared DEGs between two
metastatic melanoma
types (lymphT_skinT). SNVs were identified by using Burrows-Wheeler Aligner and Cufflinks in
metastatic melanoma
samples using RNA-seq. Sequence Alignment/Map tools and the ANNOVAR software were used to analyze and annotate SNVs. We identified 18 significantly common DEGs in lymphT_skinN and skinT_skinN and one common gene, YBX1, in lymphT_skinN, skinT_skinN, and lymphT_skinT. We identified 49,534, 48,118, 63,812, and 33,096 SNVs in skinN1, skinN2, skinT, and lymphT, respectively. Twenty-nine SNVs were located in exonic regions of two DEGs, HLA-B and TSPAN10. SNVs that exist only in tumors were located in
MARVELD1
, SLC16A3, and VAV3. The DEGs screened in our study are potential biomarkers for
metastatic melanoma
therapy.
...
PMID:Identifying differential expression genes and single nucleotide variations using RNA-seq in metastatic melanoma. 2529